RxDoctor Payments Data

Gavin Bahadur, MD

Ophthalmology · Santa Monica, CANPI 1174553994

Payments from drug & device makers

$13,224in general payments, 2019–2025

Across 18 payments — averaging $734.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$7K
  • Seagen Inc.$6K
  • Novartis$134
  • Johnson & Johnson Surgical Vision, Inc.$30
  • AbbVie$18
  • Bausch & Lomb Americas Inc.$18

What the payments were for

  • Consulting fees$5,28040%
  • Speaking & faculty fees$6,60050%
  • Travel & lodging$3763%
  • Food & beverage$9507%
  • Education$180%

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,224 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$61,920
Medicare patients
249
Services billed
499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine38$39,477
RhopressaNetarsudil Mesylate54$27,373
XiidraLifitegrast19$25,796
LumiganBimatoprost45$22,927
VyzultaLatanoprostene Bunod23$14,476
Latanoprost471$5,777
Brimonidine Tartrate87$5,489
CombiganBrimonidine Tartrate/Timolol23$5,451
Prednisolone Acetate71$3,025
Cyclosporine15$2,960
Dorzolamide-TimololDorzolamide/Timolol/Pf13$2,319
Timolol Maleate80$1,442
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$1,157
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat72$1,083
Dorzolamide Hcl19$289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$18$67,855106 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$18$40,27242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →